Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2021 13:35 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND...
March 18, 2021 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference

CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
March 09, 2021 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position

CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
March 08, 2021 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
March 01, 2021 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
March 01, 2021 08:30 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
May 22, 2020 12:35 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.

LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
May 19, 2020 08:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.

LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count...
May 14, 2020 14:13 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting

LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced that it has adjourned its special meeting of stockholders,...
May 11, 2020 08:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing

LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...